Published in Future Oncol on February 01, 2008
TGFBI expression is associated with a better response to chemotherapy in NSCLC. Mol Cancer (2010) 1.11
Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer. Cancer (2010) 1.03
Human microdosing for the prediction of patient response. Bioanalysis (2010) 0.87
Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression. PLoS One (2014) 0.81
Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells. Oncotarget (2016) 0.78
DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med (2007) 8.28
Non-small cell lung cancer. J Natl Compr Canc Netw (2010) 3.93
Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. Arch Intern Med (2008) 3.07
Racial diversity of actionable mutations in non-small cell lung cancer. J Thorac Oncol (2015) 2.80
Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest (2004) 2.73
Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res (2006) 2.68
Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res (2004) 2.54
Physician referral for fertility preservation in oncology patients: a national study of practice behaviors. J Clin Oncol (2009) 2.31
Incorporating genetic susceptibility feedback into a smoking cessation program for African-American smokers with low income. Cancer Epidemiol Biomarkers Prev (2002) 2.26
Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res (2005) 2.19
Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer. J Clin Oncol (2008) 2.18
Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol (2009) 2.13
Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol (2008) 1.97
RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene (2003) 1.95
ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest (2005) 1.93
Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol (2007) 1.91
Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene (2003) 1.88
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol (2010) 1.88
Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw (2006) 1.68
Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Res (2006) 1.68
Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol (2008) 1.61
Relationship between tumor size and survival among patients with resection of multiple synchronous lung cancers. J Thorac Oncol (2010) 1.50
Malignant pleural mesothelioma: a comprehensive review. Cancer Control (2006) 1.47
Proteomic contributions to personalized cancer care. Mol Cell Proteomics (2008) 1.46
The guinea pig syndrome: improving clinical trial participation among thoracic patients. J Thorac Oncol (2007) 1.31
Lung cancer. Practice organization. Chest (2003) 1.27
A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. J Thorac Oncol (2007) 1.25
Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. J Clin Oncol (2004) 1.23
The feasibility of online genetic testing for lung cancer susceptibility: uptake of a web-based protocol and decision outcomes. Genet Med (2008) 1.23
Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer. J Thorac Oncol (2011) 1.23
Responses to online GSTM1 genetic test results among smokers related to patients with lung cancer: a pilot study. Cancer Epidemiol Biomarkers Prev (2009) 1.22
Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol (2007) 1.19
Persistent smoking after a diagnosis of lung cancer is associated with higher reported pain levels. J Pain (2009) 1.18
Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. J Clin Oncol (2008) 1.17
Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer (2008) 1.15
Regular aspirin use and lung cancer risk. BMC Cancer (2002) 1.15
Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells. PLoS One (2012) 1.12
Obtaining DNA from a geographically dispersed cohort of current and former smokers: use of mail-based mouthwash collection and monetary incentives. Nicotine Tob Res (2004) 1.11
ID1 facilitates the growth and metastasis of non-small cell lung cancer in response to nicotinic acetylcholine receptor and epidermal growth factor receptor signaling. Mol Cell Biol (2011) 1.11
Patient-provider communication and perspectives on smoking cessation and relapse in the oncology setting. Patient Educ Couns (2009) 1.11
Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer. Oncology (2005) 1.02
Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res (2008) 1.01
Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. Lung Cancer (2004) 1.01
EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer. J Clin Oncol (2005) 1.01
Interpretation of genetic risk feedback among African American smokers with low socioeconomic status. Health Psychol (2004) 0.99
Retracted A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation. J Biol Chem (2010) 0.98
Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older. Cancer (2008) 0.98
Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells. PLoS One (2012) 0.97
Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. Curr Treat Options Oncol (2010) 0.96
Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab. J Thorac Oncol (2007) 0.96
Beta-carotene in multivitamins and the possible risk of lung cancer among smokers versus former smokers: a meta-analysis and evaluation of national brands. Cancer (2008) 0.95
Extracellular signal-regulated kinase (ERK) phosphorylates histone deacetylase 6 (HDAC6) at serine 1035 to stimulate cell migration. J Biol Chem (2013) 0.95
Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer. Oncoimmunology (2013) 0.94
Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer. J Thorac Oncol (2010) 0.93
Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol (2010) 0.90
Molecular classification of nonsmall cell lung cancer using a 4-protein quantitative assay. Cancer (2011) 0.90
High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma. Clin Cancer Res (2009) 0.90
Phase II study of neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small cell lung cancer. Chest (2005) 0.89
Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells. Cancer Biol Ther (2009) 0.89
Antiapoptotic signaling pathways in non-small-cell lung cancer: biology and therapeutic strategies. Clin Lung Cancer (2004) 0.89
Modulation of the ribonucleotide reductase M1-gemcitabine interaction in vivo by N-ethylmaleimide. Biochem Biophys Res Commun (2011) 0.88
Targeted therapy in combination with gemcitabine in non-small cell lung cancer. Semin Oncol (2003) 0.88
On Bayesian methods of exploring qualitative interactions for targeted treatment. Stat Med (2012) 0.88
Lung cancer: provoking new concepts, generating novel ideas, and rekindling enthusiasm. Cancer Control (2003) 0.88
Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma. J Immunother (2013) 0.87
Ribonucleotide reductase is not limiting for mitochondrial DNA copy number in mice. Nucleic Acids Res (2010) 0.87
Molecular predictors of chemotherapy response in non-small-cell lung cancer. Expert Rev Anticancer Ther (2007) 0.87
Prognostic significance of gelsolin expression level and variability in non-small cell lung cancer. Lung Cancer (2004) 0.86
A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors. Clin Cancer Res (2014) 0.86
Modulation of the ribonucleotide reductase-antimetabolite drug interaction in cancer cell lines. J Nucleic Acids (2010) 0.86
Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest (2007) 0.86
A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy. PLoS One (2013) 0.84
Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients. BJU Int (2010) 0.84
Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study. Clin Cancer Res (2006) 0.84
Fibroblast growth factor receptor 1 amplification in non-small cell lung cancer by quantitative real-time PCR. PLoS One (2013) 0.84
Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution. Cancer Control (2003) 0.82
Are we coming full circle for lung cancer screening a second time? Am J Respir Crit Care Med (2009) 0.82
Crizotinib: an anaplastic lymphoma kinase inhibitor. Future Oncol (2011) 0.82
Non-small cell lung cancer. J Natl Compr Canc Netw (2008) 0.81
Lung cancer patients' decisions about clinical trials and the theory of planned behavior. J Cancer Educ (2011) 0.81
Quality of care in non-small-cell lung cancer: findings from 11 oncology practices in Florida. J Oncol Pract (2011) 0.81
Thymic malignancies. J Natl Compr Canc Netw (2010) 0.81
Rupture of a cerebral arteriovenous malformation in a patient treated with bevacizumab. J Thorac Oncol (2009) 0.80
Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung cancer. Chest (2005) 0.79
Molecular analysis-based treatment strategies for non-small cell lung cancer. Cancer Control (2008) 0.79
Parameters for individualizing systemic therapy in non-small cell lung cancer. Drug Resist Updat (2010) 0.78
Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers. Cancer (2012) 0.78
Protein kinase C-beta gene variants, pathway activation, and enzastaurin activity in lung cancer. Clin Lung Cancer (2010) 0.78
Glucocorticoid receptor status is a principal determinant of variability in the sensitivity of non-small-cell lung cancer cells to pemetrexed. J Thorac Oncol (2014) 0.78
Prognostic significance of expression of p53 oncoprotein in primary (stage I-IIIa) non-small cell lung cancer. Anticancer Res (2003) 0.78
Expression of TGFbeta type-II receptor in association with markers of proliferation and apoptosis in premalignant lung lesions. Cancer (2007) 0.78
Assessment of the impact of adjunctive proactive telephone counseling to promote smoking cessation among lung cancer patients' social networks. Am J Health Promot (2013) 0.77
Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines. Cancer Chemother Pharmacol (2010) 0.77
Proactive recruitment of cancer patients' social networks into a smoking cessation trial. Contemp Clin Trials (2011) 0.76
Re: Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia. J Natl Cancer Inst (2005) 0.75